Nu-Med Plus, Inc. (NUMD) Fair Value 2026

NUMD · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (34/100)

Quick Summary — As of 2026-08-27, Nu-Med Plus, Inc. (NUMD) trades at $0.02. QOC: 4.2/10. Value Trap Risk: 34/100 (LOW). 0/13 models active.

Key Facts

Ticker
NUMD
Price
$0.02
Quality Score
4.2/10
Value Trap Risk
34/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.2/10 signals weak fundamentals

What Fair Value Does Each Model Give NUMD?

0 Intrinsic Value Models vs. Current Price ($0.02)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Nu-Med Plus, Inc. (NUMD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nu-Med Plus, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About NUMD?

0 of 13 models are currently active for NUMD. See which stocks rank higher →

How Does NUMD Rank in Medical Devices?

Among 157 Medical Devices stocks, NUMD ranks #143 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Medical Devices Stocks →

The Medical Devices sector introduces analytical considerations specific to biopharma enterprise businesses. For Nu-Med Plus, Inc., metrics like revenue per drug provide important context that general-purpose valuation models may underweight.

Is NUMD a Value Trap?

CirclFi's Value Trap algorithm assigns NUMD a score of 34/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Nu-Med Plus, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Nu-Med Plus, Inc. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NUMD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nu-Med Plus, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

AMIXAutonomix Medical, Inc.QOC 4.2PFSAProfusa, Inc.QOC 4.1NVNOenVVeno Medical CorporationQOC 4.2MOBIMobia Medical, Inc.QOC 3.9POSCPositron CorporationQOC 4.3ALMRAlamar Biosciences, Inc.QOC 3.8ITGRInteger Holdings CorporationQOC 8.2MYOMyomo, Inc.QOC 6.6SINTSintx Technologies, Inc.QOC 5.7IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: AMIX · PFSA · NVNO · MOBI · POSC · ALMR · ITGR · MYO · SINT · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to NUMD?

7 companies across all industries closest to NUMD’s Quality of Company score of 4.2/10.

TOVXTheriva Biologics, Inc.QOC 4.2VNETVNET Group, Inc.QOC 4.2CNFNCFN Enterprises Inc.QOC 4.2CNTNCanton Strategic Holdings, Inc.QOC 4.2RNTXRein Therapeutics Inc.QOC 4.2CSBACSBAQOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: TOVX · VNET · CNFN · CNTN · RNTX · CSBA · NVDA

Where Does NUMD Sit in CirclFi's Medical Devices Rankings?

NUMD is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Nu-Med Plus, Inc.’s Valuation?

What is Nu-Med Plus, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Nu-Med Plus, Inc. (NUMD). The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NUMD overvalued or undervalued right now?

At $0.02, 0 of 0 active models suggest NUMD may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Nu-Med Plus, Inc.'s business model in Medical Devices.

What does a Quality of Company score of 4.2 mean for NUMD?

Nu-Med Plus, Inc.'s QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on NUMD?

CirclFi analyzes NUMD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is NUMD a value trap in 2026?

Nu-Med Plus, Inc.'s Value Trap score is 34/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Nu-Med Plus, Inc. (NUMD) a Quality of Company score of 4.2/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/NUMD/ · Methodology
Primary sources for this NUMD valuation
  • Financial statements: Nu-Med Plus, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001543637) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NUMD as of ; valuations recomputed .